Since several studies have shown that increased serum TGF-β levels are associated with metastasis and drug resistance in ovarian cancer, we assume that targeting TGF-β signalling by a dominant-negative TGF-β receptor on CAR-T cells as a decoy appears an attractive approach to block TGF-β intracellular signal transduction and therefore enhance anti-tumour efficacy of MSLN-directed CAR T cell. This evidence concerns the gene TGFB1 and neoplasm.